Comorbidities of naïve (n=227) and biological agents failure (n=381) in patients with PsA
| Comorbidities | Group A | Group B | P value |
| Metabolic syndrome | 14 (6.2%) | 61 (16.1%) | 0.03 |
| Hypertension | 74 (32.6%) | 164 (43.1%) | 0.04 |
| Ischaemic heart disease | 10 (4.4%) | 36 (9.5%) | 0.04 |
| Dyslipidaemia | 45 (19.8%) | 117 (30.7%) | 0.03 |
| Hyperuricaemia | 33 (14.5%) | 69 (18.1%) | ns |
| Type II diabetes | 13 (5.7%) | 46 (12.1%) | 0.02 |
| Gastritis, gastric ulcer or dyspeptic disorders | 24 (10.6%) | 52 (13.6%) | ns |
| Liver disease (eg, steatosis) | 16 (7.1%) | 53 (13.9%) | 0.05 |
| Pneumopathies | 11 (4.8%) | 30 (7.9%) | ns |
| Thyroid disorder | 25 (11.1%) | 53 (13.9%) | ns |
| Osteoporosis | 15 (6.6%) | 36 (9.5%) | ns |
| Kidney failure | 3 (1.3%) | 10 (2.6%) | ns |
| Depression | 16 (7.1%) | 56 (14.7%) | 0.05 |
| Fibromyalgia | 29 (12.8%) | 73 (19.2%) | ns |
| Neurological disorders (such as neuropathy) | 8 (3.5%) | 28 (7.4%) | ns |
| Positive Mantoux RB skin test or Quantiferon TB Gold test | 12 (5.3%) | 28 (7.4%) | ns |
| Previous hepatitis B | 14 (6.2%) | 36 (9.5%) | ns |
| Previous hepatitis C | 3 (1.3%) | 11 (2.9%) | ns |
| Previous eradicated cancer | 7 (3.1%) | 24 (6.3%) | 0.05 |
P≤0.05. Values were computed by means of a χ2 test (for proportion).
Group A=naïve to TNF inhibitors; group B=TNF inhibitors and IL-12/23 inhibitors failure.
Data are expressed as frequency (absolute number and percentage).
The italics character was used to mark the p value.
IL, interleukin; ns, not statistically significant; PsA, psoriatic arthritis; TNF, tumour necrosis factor.